[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin, 2018; 68, 394−424. doi:  10.3322/caac.21492
[2] Jing ZL, Liu QM, Xie WL, et al. NCAPD3 promotes prostate cancer progression by up-regulating EZH2 and MALAT1 through STAT3 and E2F1. Cell Signal, 2022; 92, 110265. doi:  10.1016/j.cellsig.2022.110265
[3] Shih CH, Chuang LL, Tsai MH, et al. Hypoxia-Induced MALAT1 promotes the proliferation and migration of breast cancer cells by sponging miR-3064-5p. Front Oncol, 2021; 11, 658151. doi:  10.3389/fonc.2021.658151
[4] Zhang C, Yao KH, Zhang JJ, et al. Long noncoding RNA MALAT1 promotes colorectal cancer progression by acting as a ceRNA of miR-508-5p to regulate RAB14 expression. Biomed Res Int, 2020; 2020, 4157606.
[5] Ni WW, Wang XY, Sun YQ, et al. Meta-analysis of the association between MALAT1 rs619586 A>G polymorphism and cancer risk. J Int Med Res, 2020; 48. doi:  10.1177/0300060520941969
[6] Zheng HT, Shi DB, Wang YW, et al. High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. Int J Clin Exp Pathol, 2014; 7, 3174−81.
[7] Yang MH, Hu ZY, Xu C, et al. MALAT1 promotes colorectal cancer cell proliferation/migration/invasion via PRKA kinase anchor protein 9. Biochim Biophys Acta (BBA)-Mol Basis Dis, 2015; 1852, 166−74. doi:  10.1016/j.bbadis.2014.11.013
[8] Yu K, Ravoor A, Malats N, et al. A pan-cancer analysis of tumor-infiltrating B cell repertoires. Front Immunol, 2022; 12, 790119. doi:  10.3389/fimmu.2021.790119
[9] Liu M, Lang N, Qiu M, et al. miR-137 targets Cdc42 expression, induces cell cycle G1 arrest and inhibits invasion in colorectal cancer cells. Int J Cancer, 2011; 128, 1269−79. doi:  10.1002/ijc.25452
[10] Wang ML, Liu JX. Retracted: MALAT1 rs619586 polymorphism functions as a prognostic biomarker in the management of differentiated thyroid carcinoma. J Cell Physiol, 2020; 235, 1700−10. doi:  10.1002/jcp.29089